全球自體細胞療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

自體細胞療法市場預計將從 2025 年的 73.1 億美元成長到 2034 年的 453.6 億美元，2026 年至 2034 年的複合年成長率為 22.48%。

隨著個人化醫療的發展，全球自體細胞療法市場備受關注。自體細胞療法利用患者自身的細胞進行治療，進而降低免疫排斥的風險，並提高治療的適用性。這種方法正擴大應用於再生醫學和某些癌症治療領域。

自體細胞療法市場的成長受到多種因素的推動。慢性疾病盛行率的上升以及人們對再生醫學日益成長的興趣，正在促進細胞療法的研究和開發。此外，生物技術和細胞處理技術的進步也提高了這些療法的療效。

隨著臨床研究的不斷深入，自體細胞療法市場預計將持續成長。細胞分離、處理和儲存技術的進步有望帶來更佳的治療效果。此外，對再生醫學和個人化醫療領域投資的增加，預計也將推動市場的長期發展。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球自體細胞療法市場：依治療方法分類

• 市場分析、洞察與預測
• 幹細胞療法
• 非幹細胞療法

第5章 全球自體細胞療法市場：依治療領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 心血管疾病（CVD）
• 肌肉骨骼疾病
• 皮膚科
• 其他

第6章 全球自體細胞療法市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Bluebird Bio Inc
  • Novartis
  • Gilead Sciences Inc.（Kite）
  • Bristol-Myers Squibb Company
  • Pharmicell Co. Ltd
  • Johnson & Johnson（Janssen Global Services LLC.）
  • JW Therapeutics
  • Holostem SRL
  • Vertex Pharmaceuticals Inc
  • Autolus Therapeutics

The Autologous Cell Therapy Market size is expected to reach USD 45.36 Billion in 2034 from USD 7.31 Billion (2025) growing at a CAGR of 22.48% during 2026-2034.

The global autologous cell therapy market has gained significant attention as personalized medicine continues to advance. Autologous cell therapy involves using a patient's own cells for treatment, reducing the risk of immune rejection and improving treatment compatibility. This approach is increasingly used in regenerative medicine and certain cancer therapies.

Several factors are driving the growth of the autologous cell therapy market. Rising prevalence of chronic diseases and increasing interest in regenerative treatments have encouraged research and development in cell-based therapies. Additionally, advancements in biotechnology and cell processing technologies have improved the effectiveness of these therapies.

Looking ahead, the autologous cell therapy market is expected to grow as clinical research continues to expand. Improvements in cell isolation, processing, and storage techniques may enhance treatment outcomes. Furthermore, increasing investments in regenerative medicine and personalized healthcare will likely support long-term market development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy Type

• Stem Cell Therapies
• Non-Stem Cell Therapies

By Therapeutic Area

• Oncology
• Cardiovascular Disease (CVD)
• Musculoskeletal Disorders
• Dermatology
• Others

COMPANIES PROFILED

• Bluebird bio Inc, Novartis, Gilead Sciences Inc Kite, BristolMyers Squibb Company, Pharmicell Co Ltd, Johnson Johnson Janssen Global Services LLC, JW Therapeutics, Holostem Srl, Vertex Pharmaceuticals Inc, Autolus therapeutics
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AUTOLOGOUS CELL THERAPY MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. Stem Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Non-Stem Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AUTOLOGOUS CELL THERAPY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiovascular Disease (CVD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Musculoskeletal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AUTOLOGOUS CELL THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Therapy Type
  • 6.2.2 By Therapeutic Area
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Therapy Type
  • 6.3.2 By Therapeutic Area
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Therapy Type
  • 6.4.2 By Therapeutic Area
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Therapy Type
  • 6.5.2 By Therapeutic Area
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Therapy Type
  • 6.6.2 By Therapeutic Area
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL AUTOLOGOUS CELL THERAPY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Bluebird Bio Inc
  • 8.2.2 Novartis
  • 8.2.3 Gilead Sciences Inc. (Kite)
  • 8.2.4 Bristol-Myers Squibb Company
  • 8.2.5 Pharmicell Co. Ltd
  • 8.2.6 Johnson & Johnson (Janssen Global Services LLC.)
  • 8.2.7 JW Therapeutics
  • 8.2.8 Holostem S.R.L
  • 8.2.9 Vertex Pharmaceuticals Inc
  • 8.2.10 Autolus Therapeutics